Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta blockers with intrinsic sympathomimetic activity.

W B White

    American Family Physician
    |January 1, 1985
    PubMed
    Summary

    New beta-blockers with intrinsic sympathomimetic activity (ISA) offer a novel treatment for hypertension. These drugs lower blood pressure without compromising heart rate or cardiac output, expanding therapeutic options for specific patient groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension.

    Journal of the American Society of Hypertension : JASH·2016
    Same author

    Adhesion molecules, endothelin-1 and lung function in seven population-based cohorts.

    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2013
    Same author

    Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.

    Journal of human hypertension·2013
    Same author

    Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.

    Diabetes, obesity & metabolism·2013
    Same author

    Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly.

    Journal of human hypertension·2010
    Same author

    Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.

    Journal of human hypertension·2009

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Internal Medicine

    Background:

    • Emergence of a novel class of beta-adrenergic blockers.
    • These agents possess intrinsic sympathomimetic activity (ISA).
    • Focus on their application in hypertension management.

    Purpose of the Study:

    • To introduce and describe beta-blockers with ISA.
    • To elucidate their unique pharmacologic properties.
    • To identify clinical scenarios where they offer advantages over non-ISA beta-blockers.

    Main Methods:

    • Pharmacological characterization of ISA beta-blockers.
    • Analysis of their effects on blood pressure and systemic vascular resistance.
    • Evaluation of their impact on heart rate and cardiac output at rest.

    Main Results:

    • These agents effectively decrease blood pressure and systemic vascular resistance.
    • Heart rate and cardiac output remain stable at rest.
    • Demonstrated utility in patients where traditional beta-blockers are contraindicated.

    Conclusions:

    • Beta-blockers with ISA represent a significant advancement in antihypertensive therapy.
    • They provide a valuable therapeutic option for patients with conditions like sinus bradycardia, sick sinus syndrome, Raynaud-like symptoms, and COPD.
    • Expanded clinical applicability of beta-adrenergic blockade.

    Related Experiment Videos